BioTuesdays

Tag - SVB Leerink

Neovasc Logo
Markets

SVB Leerink cuts Neovasc PT to $2 from $6

SVB Leerink slashed its price target for Neovasc (NASDAQ:NVCN) to $2 from $6, citing timing uncertainty for a U.S. launch of the company’s Reducer stent for percutaneous treatment of refractory angina. The stock closed...

November 6, 2020
inflaRx
Markets

SVB Leerink ups Inflarx to OP; PT to $10 from $7

SVB Leerink upgraded Inflarx (NASDAQ:IFRX) to “outperform” from “market perform” and raised its price target to $10 from $7, citing a “significant disconnect between the promise of IFX-1 in multiple applications, most...

November 6, 2020
Spruce-Biosciences-Logo
Markets

SVB Leerink starts Spruce Biosciences at OP; PT $35

SVB Leerink launched coverage of Spruce Biosciences (NASDAQ:SPRB) with an “outperform” rating and $35 price target. The stock closed at $20.30 on Nov. 2 Spruce is a late-stage biotech company developing therapies for...

November 3, 2020
Athenex
Markets

SVB Leerink starts Athenex at OP; PT $22

SVB Leerink launched coverage of Athenex (NASDAQ:ATNX) with an “outperform” rating and $22 price target. The stock closed at $11.45 on Oct. 23. Analyst Jonathan Chang, Ph.D., writes that Athenex has leveraged its...

October 26, 2020
iTeos Logo
Markets

SVB Leerink starts iTeos Therapeutics at OP; PT $36

SVB Leerink launched coverage of iTeos Therapeutics (NASDAQ:ITOS) with an “outperform” rating and $36 price target. The stock closed at $32.92 on Aug. 18. “Though the stock has rallied since the IPO, we see potential...

August 18, 2020
AdaptHealth
Markets

SVB Leerink starts AdaptHealth at OP; PT $21

SVB Leerink launched coverage of AdaptHealth (NASDAQ:AHCO) with an “outperform” rating and $21 price target. The stock closed at $16.10 on June 30. Analyst Stephen Tanal writes that AdaptHealth is fast becoming the...

July 1, 2020
Genfit Logo
Markets

SVB Leerink slashes Genfit PT to $20 from $50

SVB Leerink slashed its price target for Genfit (NASDAQ:GNFT) to $20 from $50, but maintained its “outperform” rating, citing topline interim Phase 3 results that showed elafibranor failed to demonstrate a statistically...

May 12, 2020
CymaBay
Markets

Analysts upgrade CymaBay Therapeutics and raise PTs

Analysts for Stifel, SVB Leerink and Roth Capital Partners upgraded CymaBay Therapeutics (NASDAQ:CBAY) and raised their price targets, citing a unanimous vote by an independent review that recommend further development...

May 12, 2020
Compugen Logo
Markets

SVB Leerink starts Compugen at OP; PT $15

SVB Leerink launched coverage of Compugen (NASDAQ:CGEN) with an “outperform” rating and $15 price target. The stock closed at $13.22 on May 6. “TIGIT / PVRIG could be the next evolution in immune checkpoint blockade...

May 7, 2020
Keros Therapeutics Logo
Markets

Analysts start Keros Therapeutics at buy, OP

Analysts for H.C. Wainwright and SVB Leerink launched coverage of Keros Therapeutics (NASDAQ:KROS) with “buy” and “outperform” ratings, respectively, citing Keros’ pipeline and platform differentiation. HCW analyst...

May 4, 2020

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.